The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1458-1463

  Morton, Christopher L ^a   Wadkins, Randy M ^b   Danks, Mary K ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; IRINOTECAN;

ADVANCED CANCER; ANIMAL CELL; ANTICHOLINERGIC EFFECT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; DNA CLEAVAGE; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BUTYRYLCHOLINESTERASE; CAMPTOTHECIN; CHOLINESTERASE INHIBITORS; COS CELLS; EELS; HUMANS; MICE; MODELS, MOLECULAR; PRODRUGS;

EID: 0033118471     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. (Bethesda), 86: 836-842, 1994.
2. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
3. Rivory, L. P., Haaz, M-C., Canal, P., Lokiec, F., Armand, J-P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266. 1997.
4. Thompson, J., Zamboni, W. C., Cheshire, P. J., Richmond, L., Luo, X., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs, 8: 313-322, 1997.
5. Satoh, T., and Hosokawa, M. Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicol. Lett., 82-83: 439-445, 1995.
6. Satoh, T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamplothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharmacol. Bull. 17: 662-664, 1994.
7. Haaz, M. C., Rivory, L. P., Riche, C., and Robert, J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn-Schmiedebergs Arch. Pharmacol., 356: 257-262, 1997.
8. Whittaker, M. Cholinesterase. In: L. Beckman (ed.), Monographs in Human Genetics, Vol. 11, pp. 1-132. Basel: Karger, 1986.
9. Chatonnet, A., and Lockridge, O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J., 260: 625-634, 1989.
10. Lockridge, O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol. Ther., 47: 35-60, 1990.
11. Lockridge, O. Genetic variants of human serum butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine. In: W. Kalow (ed.), Pharmacogenetics of Drug Metabolism, pp. 15-50. New York: Pergamon Press, Inc., 1992.
12. Gandia, D., Abigerges, D., Armand, J. P., Chabot, G., Da Costa, L., De Forni, M., Mathieu-Boue, A., and Herait, P. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol., 11: 196-197, 1993.
13. Rivory, L. P., Riou, J. F., Haaz, M. C., Sable, S., Vuilhorgne, M., Commercon, A., Pond, S. M., and Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56: 3689-3694, 1996.
14. Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., and Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science (Washington DC), 253: 872-879, 1991.
15. Dewar, M. J. S., and Thiel, W. Ground states of molecules. 38. The MNDO method. Approximations and parameters. J. Am. Chem. Soc., 99: 4899-4907, 1977.
16. Dauber-Osguthorpe, P., Roberts, V. A., Osguthorpe, D. J., Wolff, J., Genest, M., and Hagler, A. T. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethorpim, a drug receptor system. Proteins, 4: 31-47, 1988.
17. Harvey, S. C. Treatment of electrostatic effects in macromolecular modeling. Proteins, 5: 78-92, 1989.
18. Beaufay, H., Amar-Costesec, A., Feytmans, E., Thines-Sempoux, D., Wibo, M., Rohbi, M., and Berthet, J. Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J. Cell. Biol., 61: 188-200, 1974.
19. Potter, P. M., Pawlik, C. A., Morton, C. L., Naeve, C. W., and Danks, M. K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res., 52: 2646-2651, 1998.
20. Dietz, A. A., Rubinstein, H. M., and Lubrano, T. Colorimetric determination of serum cholinesterase and its genetic variants by the propionyl-thiocholine-dithiobis [nitrobenzoic acid] procedure. Clin. Chem., 19: 1309-1313, 1973.
21. Augustinsson, K. B., Eriksson, H., and Faijersson, Y. A new approach to determining cholinesterase activities in samples of whole blood. Clin. Chim. Acta. 89: 239-252, 1978.
22. Ellman, G. L., Courtney, K. D., Anders, V., and Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7: 88-95, 1961.
23. Doctor, B. P., Toker, L., Roth, B., and Silman, I. Microtiter assay for acetylcholinesterase. Anal. Biochem., 166: 399-403, 1987.
24. Guichard, S., Morton, C. L., Krull, E. J., Stewart, C. F., Danks, M. K., and Potter, P. M. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin. Canter Res., 4: 3089-3094, 1998.
25. Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor tells to CPT-11. Cancer Res., 58: 20-22, 1998.
26. Harel, M., Sussman, J. L., Krejei, E., Bon, S., Chanal, P., Massoulie, J., and Silman, I. Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. Proc. Natl. Acad. Sci. USA. 89: 10827-10831, 1992.
27. Potter, P. M., Wolverton, J. S., Morton, C. L., Wierdl, M., and Danks, M. K. Cellular localization domains of a rahhit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res., 58: 3627-3632, 1998.
28. Thompson, J., Houghton, J. A., and Houghton, P. J. Responses of neuroblastoma (Nb) xenografts to systemic administration of irinotecan. Proc. Am. Assoc. Cancer Res., 37: A2976, 1996.
29. Brimijoin, S., and Hammond, P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J. Neurochem. 51: 1227-1231, 1988.